Drs Steven Feldman and Tina Bhutani-Jacques explore how next-generation oral therapies are closing the gap with biologics and reshaping psoriasis care.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep2-2026a10006a5. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Deucravacitinib Versus Placebo and Apremilast in Moderate-to-Severe Plaque Psoriasis: Efficacy and Safety Results From the 52-Week, Randomized, Double-Blinded, Placebo-Controlled Phase 3 POETYK PSO-1 Trial https://pubmed.ncbi.nlm.nih.gov/35820547/
Apremilast Prescribing Information https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Otezla/otezla_pi_english.pdf
Deucravacitinib Prescribing Information https://packageinserts.bms.com/pi/pi_sotyktu.pdf
Podden och tillhörande omslagsbild på den här sidan tillhör
Medscape. Innehållet i podden är skapat av Medscape och inte av,
eller tillsammans med, Poddtoppen.